Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Marisa Peluso, MS, Kerrie Faia, MS, David Winkler, PhD, Nidhi Patel, MS, Erin Brophy, BS, Kerry White, BA, Mark Douglas, MS, Howard M. Stern, MD PhD, Vito Palombella, PhD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD

Blood (2014) 124 (21): 328.

https://doi.org/10.1182/blood.V124.21.328.328

Published: 2014

Journal Articles

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Susan O'Brien, Manish Patel, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Pierluigi Porcu, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Howard M. Stern, MD PhD, Patrick Kelly, MD, Ian Flinn

Blood (2014) 124 (21): 3334.

https://doi.org/10.1182/blood.V124.21.3334.3334

Published: 2014

Journal Articles

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

Pierluigi Porcu, MD, Ian Flinn, Brad S. Kahl, MD, Steven M. Horwitz, MD, Yasuhiro Oki, John C. Byrd, MD, Jennifer Sweeney, Kerstin Allen, MA, Kerrie Faia, MS, Min Ni, PhD, Howard M. Stern, MD PhD, Patrick Kelly, MD, Susan O'Brien

Blood (2014) 124 (21): 3335.

https://doi.org/10.1182/blood.V124.21.3335.3335

Published: 2014

Journal Articles

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Kumudha Balakrishnan, Marisa Peluso, Min Fu, Nathalie Y. Rosin, PhD, Jan A. Burger, MD, PhD, William G. Wierda, MD, PhD, Michael J. Keating, MD, Kerrie Faia, MS, Susan O'Brien, MD, Jeff Kutok, Karen McGovern, PhD, Varsha Gandhi, PhD

Blood (2013) 122 (21): 4167.

https://doi.org/10.1182/blood.V122.21.4167.4167

Published: 2013

Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 677.

https://doi.org/10.1182/blood.V122.21.677.677

Published: 2013

Journal Articles

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Joi Dunbar, PharmD, Jylle Nevejans, Charlotte McKee, MD, Kerrie Faia, MS, Jan Jaap van Lier, MD, Peter Pruim, MSc, Janet Stegehuis, PhD, Sue Zhao, MS, Brad S. Kahl, M.D., Steven M. Horwitz, MD, Manish Patel, MD, Anas Younes, MD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 4853.

https://doi.org/10.1182/blood.V120.21.4853.4853

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only